Meeting
2011 ASCO Annual Meeting
An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM).
Authors
C. Moulton
Toronto General Hospital, Toronto, ON, Canada
C. Moulton , M. N. Levine , C. Law , R. Hart , L. Ruo , C. Gu , A. Hendler , K. Y. Gulenchyn , M. A. Haider , M. Marcaccio , V. Tandan , D. Quan , D. Jalink , R. Fairfull Smith , S. Hanna , P. D. Greig , M. Husien , T. Finch , J. A. Julian , S. Gallinger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00265356
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3520)
Abstract #
3520
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
The utility of PET scanning in colorectal cancer liver metastases being considered for surgery.
First Author: Ciara Kelly
Poster
2020 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy followed by liver resection for patients with metastatic colorectal cancer.
First Author: Rui Jin
Poster
2018 ASCO Annual Meeting
Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases. The long-term results of a randomized controlled trial (PET-CT Imaging prior to liver resection for colorectal adenocarcinoma metastases).
First Author: Pablo Emilio Serrano Aybar
Poster
2017 ASCO Annual Meeting
LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma.
First Author: Yun Shin Chun